Unicycive Therapeutics, Inc.
UNCYUnicycive Therapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapies for kidney diseases.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Unicycive Therapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapies for kidney diseases. The company utilizes an in-licensing business model to acquire promising drug candidates and leverages its management expertise to navigate the U.S. regulatory and commercial landscape. Its primary focus is addressing unmet medical needs in hyperphosphatemia and acute kidney injury.
A clinical-stage developer positioning its lead candidate as a next-generation phosphate binder with superior potency and lower pill burden compared to established standards of care.
Questions, answered.
- What is Unicycive Therapeutics, Inc.'s market cap?
- Unicycive Therapeutics, Inc. (UNCY) has a market capitalization of $140.5M and trades on NASDAQ.
- Who are Unicycive Therapeutics, Inc.'s competitors?
- Unicycive Therapeutics, Inc.'s key competitors include Akebia Therapeutics, Ardelyx, Mineralys Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Unicycive Therapeutics, Inc. partner with?
- Unicycive Therapeutics, Inc.'s notable partners include Spectrum Pharmaceuticals, Inc., Sphaera Pharma, Lee's Pharmaceutical Holdings Limited, and others.
- Where is Unicycive Therapeutics, Inc. headquartered?
- Unicycive Therapeutics, Inc. is headquartered in United States of America and employs approximately 14 people. It has been publicly traded since 2021.